Lv3
220 积分 2024-09-02 加入
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer - NCT06179069
1个月前
已完结
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
1个月前
已完结
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
1个月前
已完结
OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer
1个月前
已完结
PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)
1个月前
已完结
P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial
1个月前
已关闭
Targeting LRP1 in a rodent cervical injury model to promote functional recovery
3个月前
已关闭
皖公网安备34019202002308
